Background
==========

Stroke is the leading cause of disability and third cause of death in developed countries; an estimated 5.7 million people die of stroke annually worldwide \[[@b1-medscimonit-22-3820],[@b2-medscimonit-22-3820]\]. Ischemic stroke (IS), the most common type of stroke, accounts for approximately 85% of all strokes. Recently, various epidemiologic studies in families and twins have revealed that genetic factors played an important role in the pathogenesis of IS, including *IL1-*β, *HDAC9*, *TNF-*α, and *ACOT4* \[[@b3-medscimonit-22-3820],[@b4-medscimonit-22-3820]\]. These genetic findings permit the early detection of people at risk for IS.

Phosphodiesterase 4D (*PDE4D*) is a large gene spanning \>1.5 Mb on chromosomal region 5q1; *PDE4D* has 22 exons, 8 splice variants, and several hundred SNPs \[[@b5-medscimonit-22-3820]\]. *PDE4D* is associated with several processes involved in the occurrence of stroke, including cell proliferation, migration, and inflammation \[[@b6-medscimonit-22-3820]--[@b9-medscimonit-22-3820]\]. Recent studies showed that polymorphisms in *PDE4D* gene might be risk factors for IS \[[@b1-medscimonit-22-3820],[@b10-medscimonit-22-3820]--[@b13-medscimonit-22-3820]\]. Gretarsdottir et al. first demonstrated that SNP56 in *PDE4D* gene was associated with the IS risk via whole-genome linkage screens in the Icelandic population \[[@b14-medscimonit-22-3820]\]. To date, the following GWAS in different populations that investigated the association between *PDE4D* SNP56 and IS have produced inconclusive results. For instance, several studies suggested a positive association between SNP56 and IS susceptibility \[[@b15-medscimonit-22-3820]--[@b17-medscimonit-22-3820]\]; nevertheless, some studies could not replicate it \[[@b18-medscimonit-22-3820]--[@b21-medscimonit-22-3820]\]. These discrepancies may be due to a variety of explanations, including studies with a small sample sizes, inadequate statistical power, different analytical methods, ethnic differences, and different stroke subtypes. Meta-analysis is an efficient method to provide more credible evidence by systematically summarizing all eligible data from independent studies \[[@b22-medscimonit-22-3820]\]. To date, meta-analysis--involved SNP56 was not reported. Thus, we aimed to perform a meta-analysis to clarify the effect of *PDE4D* SNP56 on susceptibility to IS.

Material and Methods
====================

Search strategy
---------------

A comprehensive electronic search was conducted of PubMed, Embase, and Web of Science, using the keywords stroke, polymorphism OR mutation OR variant, SNP56 OR rs702553, and *PDE4D* OR phosphodiesterase 4D. The search was last performed in April 2015. The reference lists of reviews and retrieved articles were hand-checked for additional potential studies.

Inclusion and exclusion criteria
--------------------------------

Studies were considered eligible in our meta-analysis if the following criteria were fulfilled: (1) the study reported the association between *PDE4D* SNP56 and risk of ischemia stroke; (2) the study provided sufficient information of allele or genotype frequencies; (3) the study was a prospective cohort or case-control study. Comments, letters, and review articles were excluded, as were studies containing overlapping data with other studies and studies having no control population. A study reporting the results for different subpopulations was treated as separate studies.

Data extraction
---------------

The following data were extracted independently from each study by 2 authors: first author, year of publication, ethnicity of the individuals (categorized as Europeans or Asians), numbers of cases and controls, sex and mean age in cases and controls, and genotype frequency. In addition, the corresponding author was contacted for detailed data when there was insufficient information of genotype distributions.

Statistical analysis
--------------------

The odds ratios (ORs) and corresponding 95% CIs were used to measure the strength of the association between *PDE4D* SNP56 and susceptibility to IS. The significance of the pooled OR was determined by the Z test, and *P*\<0.05 was considered significant. Moreover, the pooled ORs were estimated for T *vs.* A, TT *vs.* AA (homozygote comparison), TC *vs.* AA (heterozygote comparison), TT *vs.* TA+AA (recessive model), and TT+TA *vs.* AA (dominant model). Subgroup analysis was performed according to ethnicity. Finally, the Hardy-Weinberg equilibrium (HWE) in the control group was also assessed, and a *P*\<0.05 was considered significant disequilibrium.

Heterogeneity across studies was evaluated by using the Chi-square -- based Q test and I^2^ test. For the Q test, a *P* value of \<0.05 was considered significant heterogeneity \[[@b22-medscimonit-22-3820],[@b23-medscimonit-22-3820]\]. I^2^ values range between 0% and 100%, with higher values denoting a greater degree of heterogeneity (considered when I^2^\>50%). A random-effects model (DerSimonian-Laird method) was used when *P*\<0.05 or I^2^\>50%; otherwise, a fixed-effects model (Mantel-Haenszel method) was used.\[[@b24-medscimonit-22-3820]\] A metaregression was used to investigate whether any particular covariates could explain the observed between-study heterogeneity \[[@b25-medscimonit-22-3820]\].

To evaluate the stability of the results, sensitivity analysis was performed by sequentially excluding 1 study each time, to assess the effect of a single study on the pooled ORs \[[@b26-medscimonit-22-3820]\]. Moreover, a cumulative analysis was carried out to measure the genetic effects as they accumulated over time \[[@b27-medscimonit-22-3820]\]. Publication bias was assessed using visual inspection of funnel plots and the Egger regression test; *P*\<0.05 was considered significant \[[@b28-medscimonit-22-3820]\]. All statistical analyses were performed by STATA software, version 12 (StataCorp LP, College Station, Texas, USA).

Results
=======

Characteristics of the included studies
---------------------------------------

The systematic literature search identified 68 publications in PubMed, Embase, and Web of Science. After a preliminary screening, 21 articles that met the inclusion criteria and full texts were reviewed and analyzed in detail; 7 articles reported other variants in *PDE4D* gene \[[@b29-medscimonit-22-3820]--[@b35-medscimonit-22-3820]\]. Two studies investigated the association of *PDE4D* variants with other diseases \[[@b36-medscimonit-22-3820],[@b37-medscimonit-22-3820]\]. [Figure 1](#f1-medscimonit-22-3820){ref-type="fig"} shows a flow chart of the selection process. Finally, 12 articles on *PDE4D* SNP56 and IS risk were included \[[@b14-medscimonit-22-3820]--[@b21-medscimonit-22-3820],[@b38-medscimonit-22-3820]--[@b41-medscimonit-22-3820]\]. Among them, Domingues-Montanari et al. and Matsushita et al. reported on 2 and 3 subpopulations, respectively, and were treated independently. Thus, 15 publications were included in the present meta-analysis, and the characteristics of all included studies are summarized in [Table 1](#t1-medscimonit-22-3820){ref-type="table"}.

Quantitative synthesis
----------------------

A total of 15 studies involving 19,487 subjects (including 8731 patients and 10,756 control subjects) were included in the meta-analysis. Here, we observed a wide spectrum of the T allele frequency across different ethnicities. Briefly, European control subjects carried a higher frequency of *PDE4D* SNP56 T allele (65.68±4.13%), compared with that in Asian controls (40.93±5.68%; *P*\<0.01; [Figure 2](#f2-medscimonit-22-3820){ref-type="fig"}).

The meta-analysis results of the association between the allele contrast and genetic models of the *PDE4D* SNP56 polymorphism and the susceptibility to IS was shown in [Table 2](#t2-medscimonit-22-3820){ref-type="table"}. The results of combined analyses comprising 6448 patients and 9700 controls revealed a nonsignificant association between the SNP56 variant in *PDE4D* gene and risk of IS (T *vs.* A: OR=1.01, 95%CI=0.88--1.15, *P*=0.90; TT *vs.* AA: OR=1.00, 95%CI=0.75--1.34, *P*=0.99; TA *vs.* AA: OR=1.00, 95%CI=0.83--1.21, *P*=0.98; TT+TA *vs.* AA: OR=0.99, 95%CI=0.79--1.24, *P*=0.93; TT *vs.* TA+AA: OR=1.03, 95%CI=0.86--1.25, *P*=0.74). In the subgroup analysis stratified by ethnicity, no significant association was observed between *PDE4D* SNP56 and IS susceptibility in Europeans (T *vs.* A: OR=0.96, 95%CI=0.86--1.08, *P*=0.54) or Asians (T *vs.* A: OR=1.08, 95%CI=0.80--1.44, *P*=0.62; [Figure 3](#f3-medscimonit-22-3820){ref-type="fig"}).

Test of heterogeneity
---------------------

The results showed that there was significant heterogeneity in most comparisons in the analysis of IS (T *vs.* A: *P*\<0.01 for Q test, I^2^=84.7%; TT *vs.* AA: *P*\<0.01 for Q test, I^2^=83.3%; TA *vs.* AA: *P*\<0.01 for Q test, I^2^=70.0%; TT+TA *vs.* AA: *P*\<0.01 for Q test, I^2^=81.0%; TT *vs.* TA+AA: *P*\<0.01 for Q test, I^2^=78.5%; [Table 2](#t2-medscimonit-22-3820){ref-type="table"}). We carried out metaregression analysis to assess the source of heterogeneity by ethnicity, sample sizes, and year of publication, which did not indicate any sources that contributed to the substantial heterogeneity.

Sensitivity analyses and cumulative meta-analysis
-------------------------------------------------

Sensitivity analysis showed that no single study qualitatively changed the pooled ORs, indicating that the results of this meta-analysis are highly stable ([Figure 4](#f4-medscimonit-22-3820){ref-type="fig"}). Excluding 2 studies that deviated from HWE, the pooled ORs did not change at all. \[Data not shown,\] Cumulative meta-analysis conducted by publication year demonstrated that estimated pooled ORs tended to be stable with the accumulation of more data over time ([Figure 5](#f5-medscimonit-22-3820){ref-type="fig"}).

Publication bias
----------------

Funnel plots and the Egger test were performed to assess publication bias. As shown in [Figure 6](#f6-medscimonit-22-3820){ref-type="fig"}, the shapes of the funnel plots did not show any evidence of obvious asymmetry for *PDE4D* SNP56 and IS. In addition, the results of the Egger test also did not show any evidence of publication bias: T *vs.* A: *P*=0.53, TT *vs.* AA: *P*=0.52, TA *vs.* AA: *P*=0.22, TT+TA *vs.* AA: *P*=0.24, TT *vs.* TA+AA: *P*=0.76.

Discussion
==========

Despite substantial progress in prevention and treatment, stroke, a multifactorial disease, remains the leading cause of disability and is also responsible for 10% of deaths each year in developed countries \[[@b2-medscimonit-22-3820],[@b42-medscimonit-22-3820]\]. Previous studies showed that development of IS can be attributed to environmental and genetic factors \[[@b1-medscimonit-22-3820],[@b43-medscimonit-22-3820]\]. In the last few decades, a series of genetic studies have provided evidence supporting an important role for genetics in the pathogenesis of IS, such as variants in interleukin-6, leptin receptor, and angiotensin-converting enzyme \[[@b44-medscimonit-22-3820]--[@b46-medscimonit-22-3820]\].

One of the widely studied candidate genes was *PDE4D*, which belongs to a large superfamily of phosphodiesterases (PDEs). *PDE* genes encode PDE enzyme, which can regulate cAMP levels and is also the key signal transduction molecule in multiple tissues, including kidney, macrophages, B and T lymphocytes, monocytes, as well as vascular smooth muscle cells \[[@b47-medscimonit-22-3820],[@b48-medscimonit-22-3820]\]. Moreover, several studies have demonstrated that *PDE4D* was associated with cell proliferation, migration, and inflammation -- processes involved in stroke occurrence \[[@b6-medscimonit-22-3820]--[@b9-medscimonit-22-3820]\]. The association between specific *PDE4D* SNP56 and IS was initially identified via GWAS by the deCODE group \[[@b14-medscimonit-22-3820]\]. However, replication of these results in other populations has proven difficult. A meta-analysis is a proper method that can overcome the problem of small sample sizes and inadequate statistical power in different genetic studies by combining results from individual studies. To date, accumulated meta-analysis has been performed to clarify the association of genetic polymorphisms with IS risk. Variants in several genes were identified as risk factors for IS, including *apolipoprotein B*, *beta-2 adrenergic receptor*, methylenetetrahydrofolate reductase (*MTHFR),* and *HDAC9* \[[@b49-medscimonit-22-3820]--[@b53-medscimonit-22-3820]\]. However, some other variants, such as *IL-6* G572C, *PON1* L55M, and *CYP11B2* C-344T were not associated with susceptibility to IS \[[@b44-medscimonit-22-3820],[@b54-medscimonit-22-3820],[@b55-medscimonit-22-3820]\]. Thus, we saw the need to perform a meta-analysis aimed to investigate the contribution of SNP56 in the *PDE4D* gene to IS.

In this comprehensive meta-analysis involving 8731 patients and 10,756 controls, the results showed a wide spectrum of T allele frequency of *PDE4D* SNP56 across different ethnicities. Compared with Asian controls, European controls carried a higher frequency of T allele (Asians *vs.* Europeans: 40.93±5.68% and 65.68±4.13%, respectively; *P*\<0.01). It is widely accepted that genetic markers in predisposition to IS vary across different ethnic populations. For instance, *MTHFR* A1298C polymorphism was strongly associated with IS risk in Asians but not in Europeans \[[@b56-medscimonit-22-3820]--[@b58-medscimonit-22-3820]\]. These results suggested that *PDE4D* SNP56 might be an ethnic population -- specific genetic marker for IS patients.

In the overall analysis, we found that SNP56 in the *PDE4D* gene might not be significantly associated with IS risk. Subsequently, in the subgroup analysis stratified by ethnicity, no significant association between SNP56 and susceptibility to IS was found in either European or Asian population. However, the results might not be conclusive because IS is a complex multifactorial disease and environmental factors also play an important role in the development of IS \[[@b1-medscimonit-22-3820],[@b2-medscimonit-22-3820],[@b42-medscimonit-22-3820]\]. Thus, the lack of association might also be attributed to variations in climate and in lifestyle, diet, and economic status of different individuals.

Heterogeneity was significant for the most comparisons of *PDE4D* SNP56 and IS risk. We then performed subgroup analysis and metaregression to identify the source of heterogeneity. The results of metaregression did not show any sources that contribute to the heterogeneity, including year of publication, sample size, and ethnicity. However, subtype information of IS might contribute to the significant heterogeneity \[[@b59-medscimonit-22-3820]\]. For example, the significant association in the first GWAS was strongest for carotid and cardiogenic stroke \[[@b14-medscimonit-22-3820]\]. In this meta-analysis, it is difficult to carry out a subgroup analysis by stroke subtype because of the lack of sufficient data. Additionally, hypertension status of patients and controls also accounted for the heterogeneity \[[@b60-medscimonit-22-3820]\]. Compared with those with normal blood pressure, patients with hypertension were at a higher risk for diabetes, another stroke risk factor \[[@b61-medscimonit-22-3820]\]. Thus, it might be easier to discern the effect of *PDE4D* SNP56 on IS risk in the absence of hypertension. Moreover, a difference in the proportion of hypertensives might also contribute to the inconsistent results.

This meta-analysis significantly increased statistical power by pooling data from different studies; however, several limitations of this meta-analysis need to be considered for interpretation of our results. First, significant heterogeneity between studies was observed in the current meta-analysis, which might be attributed to different genetic backgrounds, different lifestyles, distinct environments, stroke subtypes, hypertension status, and abnormal physiologic variables. Second, we only included studies published in English, which might introduce a language bias. Distinct IS subtypes had different risk factors and etiologies, thus a subgroup analysis by types of IS was necessary in further meta-analysis. Finally, the development of IS is multifactorial, including genetic and environmental factors. Insufficient data prevented us from performing gene-environment or gene-gene interactions.

Conclusions
===========

In conclusion, despite these limitations, the current meta-analysis included 15 genetic studies suggested that SNP56 in *PDE4D* gene might not be associated with the susceptibility to IS both in Europeans and Asians. Further well-designed studies with large sample size are required to validate our results. Moreover, gene-gene and gene-environment interactions should also be investigated to clarify possible roles of multiple risk factors in the development of IS.
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![Study selection procedures for a meta-analysis of *PDE4D* SNP56 variant and ischemic stroke risk.](medscimonit-22-3820-g001){#f1-medscimonit-22-3820}

![T allele frequencies (%) of *PDE4D* SNP56 in European or Asian control groups. Each data point represents a separate study for the indicated association.](medscimonit-22-3820-g002){#f2-medscimonit-22-3820}

![Forest plot of ischemic stroke risk associated with *PDE4D* SNP56 variant. The strength of the association was calculated by the odds ratios and corresponding 95% CIs. The sizes of the squares reflect the weighting of included studies; the center of diamonds reflects summary effect, and the left and right extremes of diamonds reflect 95% CI.](medscimonit-22-3820-g003){#f3-medscimonit-22-3820}

![Sensitivity analysis for the association between *PDE4D* SNP56 and ischemic stroke risk. Results were computed by omitting each study (left column) in turn. Bars represent 95% CIs.](medscimonit-22-3820-g004){#f4-medscimonit-22-3820}

![Cumulative meta-analyses of the association between *PDE4D* SNP56 and ischemic stroke risk. Pooled odds ratio estimates with the corresponding 95% CI as information accumulates at the end of each year (left column). Bars represent 95% CIs.](medscimonit-22-3820-g005){#f5-medscimonit-22-3820}

![Funnel plots of the association between *PDE4D* SNP56 and ischemic stroke risk. No significant funnel asymmetry that could indicate publication bias was observed. Logor -- natural logarithm of the odds ratio; SE -- standard error.](medscimonit-22-3820-g006){#f6-medscimonit-22-3820}

###### 

Characteristics of Eligible Studies in a Meta-analysis of the *PDE4D* SNP56 and ischemic stroke risk.

  First author          Year   Ethnicity   Cases   Controls                                            
  --------------------- ------ ----------- ------- ----------- ------ ------ ------ ----------- ------ ------
  Brophy                2006   Europeans   248     73.9±5.9    NR     56.5   560    70.3±4.5    NR     32.7
  Domingues-Montanari   2010   Europeans   527     70.6±11.9   54.5   59.2   263    72.1±6.9    45.7   44.7
  Domingues-Montanari   2010   Europeans   565     52.4±9.3    63.9   57.2   518    63.0±6.8    45.9   37.7
  Sun                   2009   Asians      649     73.2±9.4    56.0   71.3   761    73.3±7.3    55     48.2
  Matsushita            2009   Asians      24      NR          NR     NR     1566   NR          NR     NR
  Matsushita            2009   Asians      1112    70.2±10.0   60.7   78.1   1112   70.1±10.1   60.7   53.7
  Matsushita            2009   Asians      1711    69.0±9.3    64.7   75.4   1786   64.8±15.4   54.3   52.2
  Gretarsdottir         2003   Europeans   864     NR          NR     NR     908    NR          NR     NR
  Kuhlenbäumer          2006   Europeans   1181    66.9±14.6   54.0   77.0   1569   55.9±13.7   49.0   41.0
  Lin                   2007   Asians      190     NR          NR     NR     211    NR          NR     NR
  Munshi                2012   Asians      516     49.3±17.3   69.8   53.2   513    49.0±16.8   69.8   29.6
  Staton                2006   Europeans   151     67.3±11.7   66.2   NR     164    66.1±11.8   62.8   NR
  Zee                   2006   Europeans   259     62.1±0.5    Nr     19.8   259    61.7±0.5    NR     15.5
  Meschia               2005   Europeans   377     64.8±15.0   53.6   68.5   263    60.0±14.7   38.0   38.8
  Woo                   2006   Europeans   357     69.0        43.7   NR     303    68.0        44.2   NR

NR -- not report.

###### 

Summary ORs and heterogeneity of the *PDE4D* SNP56 and risk of ischemic stroke.

  Comparison       Variables   No. of studies      Test of association   Model   Test of heterogeneity            
  ---------------- ----------- ------------------- --------------------- ------- ----------------------- -------- --------
  T *vs.* A        Overall     15                  1.01 (0.88--1.15)     0.90    R                       84.7     \<0.01
  Europeans        9           0.96 (0.86--1.08)   0.54                  R       65.8                    \<0.01   
  Asians           6           1.08 (0.80--1.44)   0.62                  R       92.2                    \<0.01   
  TT *vs.* AA      Overall     13                  1.00 (0.75--1.34)     0.99    R                       83.3     \<0.01
  Europeans        7           0.89 (0.67--1.18)   0.42                  R       61.8                    0.02     
  Asians           6           1.16 (0.68--1.99)   0.58                  R       90.5                    \<0.01   
  TA *vs.* AA      Overall     13                  1.00 (0.83--1.21)     0.98    F                       70.0     0.12
  Europeans        7           0.92 (0.73--1.15)   0.46                  R       41.5                    \<0.01   
  Asians           6           1.09 (0.81--1.47)   0.57                  R       81.0                    \<0.01   
  TT+TA *vs.* AA   Overall     13                  0.99 (0.79--1.24)     0.93    R                       81.0     \<0.01
  Europeans        7           0.91 (0.72--1.16)   0.45                  R       53.9                    0.04     
  Asians           6           1.09 (0.75--1.57)   0.65                  R       89.1                    \<0.01   
  TT *vs.* TA+AA   Overall     13                  1.03 (0.86--1.25)     0.74    R                       78.5     \<0.01
  Europeans        7           0.97 (0.79--1.18)   0.76                  R       69.4                    \<0.01   
  Asians           6           1.13 (0.76--1.69)   0.54                  R       85.9                    \<0.01   

OR -- odds ratio; CI -- confidence interval.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
